Edition:
United States

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

62.99USD
24 May 2019
Change (% chg)

$0.30 (+0.48%)
Prev Close
$62.69
Open
$63.30
Day's High
$64.83
Day's Low
$62.38
Volume
105,246
Avg. Vol
135,718
52-wk High
$69.60
52-wk Low
$22.00

Latest Key Developments (Source: Significant Developments)

Uniqure Announces First Quarter 2019 Results And Highlights Recent Company Progress
Monday, 29 Apr 2019 07:00am EDT 

April 29 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES FIRST QUARTER 2019 RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q1 LOSS PER SHARE $0.74.Q1 REVENUE $1.1 MILLION VERSUS $3.5 MILLION.Q1 REVENUE ESTIMATE $1.9 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.71 -- REFINITIV IBES DATA.  Full Article

Uniqure Gets FDA Fast Track Designation For Amt-130 Gene Therapy
Monday, 8 Apr 2019 07:02am EDT 

April 8 (Reuters) - Uniqure NV ::UNIQURE RECEIVES FDA FAST TRACK DESIGNATION FOR AMT-130 GENE THERAPY FOR THE TREATMENT OF HUNTINGTON’S DISEASE.UNIQURE NV - NEARING INITIATION OF A PHASE I/II STUDY OF AMT-130.UNIQURE NV - ON TRACK TO TREAT FIRST PATIENT IN SECOND HALF OF 2019.  Full Article

Uniqure Announces 2018 Financial Results
Thursday, 28 Feb 2019 07:00am EST 

Feb 28 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.UNIQURE NV - COMPANY CURRENTLY EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2021.  Full Article

uniQure NV Announces Updated Clinical Data From Phase IIb Study Of Gene Therapy AMT-061 In Hemophilia B Patients
Friday, 8 Feb 2019 07:00am EST 

Feb 8 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES UPDATED CLINICAL DATA FROM PHASE IIB STUDY OF AMT-061 IN PATIENTS WITH HEMOPHILIA B.UNIQURE - DATA SHOW ALL THREE PATIENTS HAVE DEMONSTRATED INCREASING AND SUSTAINED FIX LEVELS AFTER ONE-TIME ADMINISTRATION OF AMT-061.UNIQURE - DATA SHOW MEAN FIX ACTIVITY FOR THREE PATIENTS AT TWELVE WEEKS INCREASED TO 38% OF NORMAL.UNIQURE - STUDY SHOWS AMT-061 HAS POTENTIAL TO INCREASE FIX ACTIVITY INTO NORMAL RANGE, CONTINUES TO BE WELL TOLERATED, WITH NO SERIOUS ADVERSE EVENTS.  Full Article

Uniqure Announces FDA Clearance Of Investigational New Drug Application For Amt-130 In Huntington’S Disease
Tuesday, 22 Jan 2019 07:00am EST 

Jan 22 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AMT-130 IN HUNTINGTON’S DISEASE.UNIQURE NV - EXPECTS TO OPEN SEVERAL CLINICAL SITES IN UNITED STATES AND BEGIN DOSING PATIENTS IN H2 FOR AMT-130.  Full Article

Uniqure announces long-term clinical data from ongoing phase I/Ii trial of AMT-060
Monday, 3 Dec 2018 07:00am EST 

Dec 3 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 AND CONFIRMS DOSE FOR AMT-061 PIVOTAL STUDY IN HEMOPHILIA B.UNIQURE NV - DOSE CONFIRMED FOR PHASE III PIVOTAL STUDY OF AMT-061, WITH PATIENT DOSING EXPECTED TO COMMENCE IN Q1 OF 2019.UNIQURE NV - AMT-060 CONTINUES TO BE SAFE AND WELL-TOLERATED, WITH NO NEW SERIOUS ADVERSE EVENTS AND NO DEVELOPMENT OF INHIBITORS.  Full Article

Uniqure Announces Initial Topline Data From Dose-Confirmation Study Of AMT-061 In Patients With Hemophilia B
Thursday, 15 Nov 2018 08:21am EST 

Nov 15 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES INITIAL TOPLINE DATA FROM DOSE-CONFIRMATION STUDY OF AMT-061 IN PATIENTS WITH HEMOPHILIA B.UNIQURE - IN STUDY, ALL PATIENTS ACHIEVED THERAPEUTIC FACTOR IX ACTIVITY WITH MEAN FIX LEVEL OF 31% OF NORMAL AT 6 WEEKS AFTER ADMINISTRATION.UNIQURE - AMT-061 HAS BEEN WELL-TOLERATED.UNIQURE - EXPECTS TO SUBMIT DATA FROM PHASE IIB DOSE-CONFIRMATION STUDY OF AMT-061 TO FDA & EMA BY END OF THE YEAR.UNIQURE - EXPECTS TO INITIATE DOSING PHASE OF ITS PHASE III HOPE-B PIVOTAL STUDY IN Q1 2019.  Full Article

Uniqure Announces Third Quarter 2018 Financial Results
Tuesday, 6 Nov 2018 07:00am EST 

Nov 6 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS COMPANY PROGRESS.Q3 LOSS PER SHARE $0.59.Q3 REVENUE $3.1 MILLION VERSUS I/B/E/S VIEW $2.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.CURRENTLY EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2021.  Full Article

uniQure Q3 Loss Per Share $0.59
Tuesday, 6 Nov 2018 07:00am EST 

Nov 6 (Reuters) - Uniqure NV ::UNIQURE ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS COMPANY PROGRESS.Q3 LOSS PER SHARE $0.59.Q3 REVENUE $3.1 MILLION VERSUS I/B/E/S VIEW $2.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.  Full Article

uniQure NV Quarterly Loss Per Share $0.59
Tuesday, 6 Nov 2018 06:28am EST 

Nov 6 (Reuters) - Uniqure NV ::UNIQURE NV QUARTERLY LOSS PER SHARE $0.59.UNIQURE NV QUARTERLY TOTAL REVENUES $3.1 MILLION VERSUS $2.3 MILLION.  Full Article

UniQure gene therapy shows promising result in mid-stage trial

Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.